Global pharma major Lupin Limited (Lupin) announced the launch of rocuronium bromide injection, 50 mg/5 mL (10 mg/mL) and 100 mg/10 mL (10 mg/mL) multiple-dose vials, after Lupin’s alliance partner Caplin Steriles Limited (Caplin) received an approval for its ANDA from the United States Food and Drug Administration (FDA).
Rocuronium bromide injection, 50 mg/5 mL (10 mg/mL) and 100 mg/10 mL (10 mg/mL) multiple-dose vials is the generic version of Zemuron injection, 50 mg/5 mL and 100 mg/10 mL of Organon USA Inc. and is indicated for inpatients and outpatients as an adjunct to general anaesthesia to facilitate both rapid sequence and routine tracheal intubation, and to provide skeletal muscle relaxation during surgery or mechanical ventilation.
Lupin is an innovation-led transnational pharmaceutical company headquartered in Mumbai, India. The company develops and commercializes a wide range of branded and generic formulations, biotechnology products, and APIs in over 100 markets in the US, India, South Africa, and across the Asia Pacific (APAC), Latin America (LATAM), Europe, and Middle East regions.
